Literature DB >> 4597724

Effect of rifampin on the immune response in guinea pigs.

B M Dajani, J E Kasik, J S Thompson.   

Abstract

The effect of an oral dose of 20 mg of rifampin per kg per day on the immune response to killed Mycobacterium bovis var. BCG, 1-chloro-2,4-dinitrobenzene (DNCB), and sheep red blood cells (SRBC) was studied in adult female guinea pigs. Fully established cutaneous reactions to BCG or DNCB were markedly reduced during rifampin treatment but reverted to pretreatment levels after the drug was discontinued. When treatment was begun 7 days after immunization, positive reactions did not occur during drug administration but developed after cessation. When treatment was initiated 7 days before immunization, the response to these agents was completely suppressed during but also after rifampin was discontinued, suggesting that recognition and processing of the immunogens had been impaired. Rifampin had no effect on the secondary response to SRBC. When treatment was initiated either 7 days before or 2, 3, or 4 days after SRBC immunization, the primary response was abolished, but the reaction to a booster after drug withdrawal varied: some animals developed a normal secondary hemagglutinin response, but the majority reacted as if they had not been previously immunized. These studies indicate that rifampin is an active immunosuppressive agent in the guinea pig.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4597724      PMCID: PMC444433          DOI: 10.1128/AAC.3.4.451

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  [Immunosuppressive action of rifampicin].

Authors:  B Serrou; C Solassol; L Karcenty; H Joyeux; H Pujol
Journal:  Nouv Presse Med       Date:  1972-05-06

2.  Rifampicin: an immunosuppressant?

Authors:  B M Dajani; M S Canady; J S Thompson; J E Kasik
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

3.  Rifampicin: an immunosuppressant?

Authors:  B S Nilsson
Journal:  Lancet       Date:  1971-08-14       Impact factor: 79.321

4.  [Pediatric clinical experimentation with rifampicin. Therapeutic effect and tolerance].

Authors:  G Valente; A Luvarà
Journal:  Clin Pediatr (Bologna)       Date:  1969-01

5.  Rifampin in treatment of advanced pulmonary tuberculosis. Report of a VA cooperative pilot study.

Authors:  J W Raleigh
Journal:  Am Rev Respir Dis       Date:  1972-03

6.  In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin.

Authors:  E Păunescu
Journal:  Nature       Date:  1970-12-19       Impact factor: 49.962

7.  Rifampin: effect of two-day treatment on the meningococcal carrier state and the relationship to the levels of drug in sera and saliva.

Authors:  L F Devine; D P Johnson; S L Rhode; C R Hagerman; W E Pierce; R O Peckinpaugh
Journal:  Am J Med Sci       Date:  1971-02       Impact factor: 2.378

8.  Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial.

Authors:  R Newman; B Doster; F J Murray; S Ferebee
Journal:  Am Rev Respir Dis       Date:  1971-04

9.  Quantitative semi-micro hemagglutination. A sensitive assay dependent upon cellular dissociation and migration in capillary tubes.

Authors:  C D Severson; J S Thompson
Journal:  J Immunol       Date:  1966-05       Impact factor: 5.422

10.  Antibody formation. IV. Formation of rapidly and slowly sedimenting antibodies and immunological memory to bacteriophage phi-X 174.

Authors:  J W UHR; M S FINKELSTEIN
Journal:  J Exp Med       Date:  1963-03-01       Impact factor: 14.307

  10 in total
  8 in total

1.  Immunosuppressant activity of the ansamycins.

Authors:  J E Kasik; M Monick; J S Thompson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

2.  Antibiotics and suppression of lymphocyte function in vitro.

Authors:  G Banck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Comparison of antibacterial and antiimmune effects of certain rifamycins.

Authors:  J E Kasik; M Monick
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

4.  Effect of rifampin on the immune response in mice.

Authors:  A Bellahsène; A Forsgren
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

5.  Immunological responsiveness of tuberculosis patients receiving rifampin.

Authors:  F L Ruben; A Winkelstein; I G Fotiadis
Journal:  Antimicrob Agents Chemother       Date:  1974-04       Impact factor: 5.191

6.  Rifampicin-induced suppression of antitumor immunity.

Authors:  W Roszkowski; R Lipinska; K Roszkowski; J Jeljaszewicz; G Pulverer
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

7.  Effect of rifampin, levamisole, and cytoplasmic protein antigen from Mycobacterium microti on 5'-nucleotidase production by guinea pig macrophages.

Authors:  A P Bautista
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Effect of rifampin on cutaneous hypersensitivity to purified protein derivative in humans.

Authors:  P Mukerjee; S Schuldt; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.